Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials
Authors
Keywords
Breast cancer, Fulvestrant, Targeted therapy, Meta-analysis
Journal
Breast Cancer
Volume 24, Issue 3, Pages 345-352
Publisher
Springer Nature
Online
2017-03-21
DOI
10.1007/s12282-017-0770-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice
- (2016) Valentina Sini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
- (2016) Jill M. Spoerke et al. Nature Communications
- FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2015) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
- (2015) Khalil Zaman et al. EUROPEAN JOURNAL OF CANCER
- New directions for drug-resistant breast cancer: the CDK4/6 inhibitors
- (2015) Mark Nichols Future Medicinal Chemistry
- Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
- (2015) Miguel Martín et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
- (2014) Mark J. Clemons et al. BREAST CANCER RESEARCH AND TREATMENT
- Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
- (2013) David M. Hyams et al. INVESTIGATIONAL NEW DRUGS
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
- (2013) A. D. Leo et al. JNCI-Journal of the National Cancer Institute
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
- (2013) John FR Robertson et al. LANCET ONCOLOGY
- Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
- (2013) Shannon Cope et al. VALUE IN HEALTH
- FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive Changes Result in Activation of Alternate Signaling Pathways and Acquisition of Resistance to Aromatase Inhibitors
- (2011) A. Brodie et al. CLINICAL CANCER RESEARCH
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
- (2010) Xiaohong R. Yang et al. JNCI-Journal of the National Cancer Institute
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now